This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML) (m-FLAI)

This study has been completed.
Information provided by:
Seoul National University Hospital Identifier:
First received: November 17, 2010
Last updated: November 23, 2010
Last verified: November 2010
A phase II clinical trial evaluating the efficacy and tolerability of induction and consolidation chemotherapy comprising Fludarabine, cytarabine and attenuated-dose Idarubicin (modified-FLAI) in the elderly patients with acute myeloid leukemia.

Condition Intervention Phase
Acute Myeloid Leukemia Drug: induction chemotherapy (fludarabine, cytarabine, idarubicin) Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Phase 2 Clinical Trial Evaluating the Efficacy and Tolerability of Induction and Consolidation Chemotherapy Comprising Fludarabine, Cytarabine, and Attenuated-dose Idarubicin in Elderly Patients With AML(Acute Myeloid Leukemia)

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Complete remission rate
    Rate of complete remssion (CR) after two cycles of m-FLAI induction

Secondary Outcome Measures:
  • Rate of serious adverse events (SAE)
    Number of patients dying from SAE related to m-FLAI induction

  • Event Free Survival
    Event free survival defined as a period from study enrollment to death by from cause or relapse of disease after complete remission

  • overall survival
    Overall survival defined as a period from study enrollment to death from any cause

  • Predictive factors for Complete remission
    Compare complete remission rate according to existence of specific chromosome abnormality and Charlson comorbidity index to evaluate predicative impact of these factors.

Enrollment: 108
Study Start Date: June 2007
Study Completion Date: July 2010
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: induction chemotherapy (fludarabine, cytarabine, idarubicin)
    fludarabine, cytarabine, idarubicin

Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • previously untreated AML (excluding acute promyelocytic leukemia)
  • age greater than 60 years old
  • ECOG PS (Eastern Cooperative Oncology Group Performance scale) less than 2
  • adequate hepatic/ renal/ cardiac function

Exclusion Criteria:

  • acute promyelocytic leukemia
  • significant cardiac disease
  • combined non-hematologic malignancy
  • aleukemic leukemia (only granulocytic sarcoma)
  • CNS (Central Nervous system) involvement
  • significant comorbidity/ uncontrollable bleeding tendency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01247493

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: Inho Kim professor
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kim, Inho professor, SeoulNUH Identifier: NCT01247493     History of Changes
Other Study ID Numbers: H-0704-029-205
Study First Received: November 17, 2010
Last Updated: November 23, 2010

Keywords provided by Seoul National University Hospital:

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Fludarabine phosphate
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors processed this record on September 21, 2017